Title |
Costs Associated with Febrile Neutropenia in the US
|
---|---|
Published in |
PharmacoEconomics, December 2012
|
DOI | 10.2165/11592980-000000000-00000 |
Pubmed ID | |
Authors |
Shannon L. Michels, Rich L. Barron, Matthew W. Reynolds, Karen Smoyer Tomic, Jingbo Yu, Gary H. Lyman |
Abstract |
Febrile neutropenia (FN) is a potentially life-threatening condition that may develop in cancer patients treated with myelosuppressive chemotherapy and result in considerable costs. This study was designed to estimate US healthcare utilization and costs in those experiencing FN by location of care, tumour type and mortality. |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Korea, Republic of | 1 | 2% |
Unknown | 43 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 9 | 20% |
Researcher | 6 | 14% |
Student > Ph. D. Student | 5 | 11% |
Student > Bachelor | 3 | 7% |
Student > Doctoral Student | 2 | 5% |
Other | 8 | 18% |
Unknown | 11 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 23 | 52% |
Agricultural and Biological Sciences | 3 | 7% |
Nursing and Health Professions | 1 | 2% |
Mathematics | 1 | 2% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
Other | 4 | 9% |
Unknown | 11 | 25% |